The 27-week growth-restricted neonate typically has a better prognosis than the 24-week normal-size neonate.
Gestational age is the single most powerful predictor of survival and neurodevelopmental outcomes in periviable births, outweighing the impact of growth restriction. Each additional week of gestation dramatically improves both mortality and long-term morbidity outcomes 1.
Survival Data
The survival advantage of the 27-week infant is substantial:
- 24 weeks gestation: 42-59% survival to discharge 1
- 25 weeks gestation: 67-76% survival to discharge 1
- 27 weeks gestation: Would be expected to have >80% survival based on the progressive improvement trend
Even accounting for growth restriction in the 27-week infant, the gestational age advantage is decisive. Research specifically examining very low birth weight infants found that only gestational age at delivery was independently related to composite adverse outcomes (death or adverse neurodevelopmental outcome), whereas diagnosis of intrauterine growth restriction was not 2.
Neurodevelopmental Outcomes
The neurodevelopmental advantage of additional gestational age is equally compelling:
At 24 weeks: 30% of survivors have severe or moderate impairment at 30 months, with 28% having moderate-to-severe neurodevelopmental impairment at 4-8 years 1
At 25 weeks: 17% have severe or moderate impairment at 30 months, with 24% having moderate-to-severe neurodevelopmental impairment at 4-8 years 1
At 27 weeks: The trend continues with progressively better outcomes
Growth Restriction Considerations
While growth restriction does increase neonatal morbidity risks, the impact is substantially less than the effect of prematurity itself:
- Growth-restricted preterm infants (when confirmed as small for gestational age <10th percentile at birth) show increased rates of bronchopulmonary dysplasia, retinopathy of prematurity, and necrotizing enterocolitis 3
- However, gestational age remains the dominant factor in determining overall survival and neurodevelopmental outcomes 2
- The 3-week gestational age advantage (24 vs 27 weeks) provides more benefit than the disadvantage of growth restriction
Clinical Reasoning
The guideline evidence emphasizes that multiple factors affect periviable outcomes beyond gestational age, including fetal weight, but gestational age consistently emerges as the primary determinant 1. The dramatic improvement in outcomes with each additional week of gestation—particularly in the 24-27 week range where both infants fall—means the 27-week infant starts from a fundamentally better baseline.
Important Caveats
- Individual outcomes cannot be predicted with certainty; these are population-level probabilities 1
- The degree of growth restriction matters—severe growth restriction (<3rd percentile) carries worse prognosis than mild restriction 3, 4
- Antenatal interventions (corticosteroids, magnesium sulfate) and delivery at a tertiary center with level III/IV NICU capabilities significantly improve outcomes for both infants 1
- Postnatal management quality affects outcomes, but the gestational age advantage persists across different care settings 5